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ABSTRACT
Objectives: Current strategies for motor recovery after spinal cord injury (SCI) aim to facilitate motor performance through
modulation of afferent input to the spinal cord using epidural electrical stimulation (EES). The dorsal root ganglion (DRG) itself,
the first relay station of these afferent inputs, has not yet been targeted for this purpose. The current study aimed to deter-
mine whether DRG stimulation can facilitate clinically relevant motor response in motor complete SCI.
Materials and Methods: Five patients with chronic motor complete SCI were implanted with DRG leads placed bilaterally on
level L4 during five days. Based on personalized stimulation protocols, we aimed to evoke dynamic (phase 1) and isotonic
(phase 2) motor responses in the bilateral quadriceps muscles. On days 1 and 5, EMG-measurements (root mean square [RMS]
values) and clinical muscle force measurements (MRC scoring) were used to measure motor responses and their
reproducibility.
Results: In all patients, DRG-stimulation evoked significant phase 1 and phase 2 motor responses with an MRC ≥4 for all upper
leg muscles (rectus femoris, vastus lateralis, vastus medialis, and biceps femoris) (p < 0.05 and p < 0.01, respectively), leading
to a knee extension movement strong enough to facilitate assisted weight bearing. No significant differences in RMS values
were observed between days 1 and 5 of the study, indicating that motor responses were reproducible.
Conclusion: The current paper provides first evidence that bilateral L4 DRG stimulation can evoke reproducible motor
responses in the upper leg, sufficient for assisted weight bearing in patients with chronic motor complete SCI. As such, a new
target for SCI treatment has surfaced, using existing stimulation devices, making the technique directly clinically accessible.
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INTRODUCTION
Spinal cord injury (SCI) is one of the most devastating injuries
to the human central nervous system, leading to a multitude of
problems including loss of autonomic control, muscle atrophy,
spasticity, and most prominently, sensory and motor impairments
(1, 2). The motor impairments originate from a disconnection
between descending pathways and spinal circuits caudal to the
lesion, depriving the latter of synaptic input necessary for genera-
tion and control of motor responses (3).
One of the current experimental strategies aimed at motor
recovery after SCI is epidural neuromodulation of the spinal cord,
also known as (epidural) spinal cord stimulation ((e)SCS) or epidu-
ral electrical stimulation (EES) (4–8). Both in preclinical (9–11) and
clinical experimental settings (4, 5, 12–14), EES in combination
with rehabilitation was able to facilitate regain of (voluntary)
motor control in motor incomplete and motor complete SCI.
Although the exact circuit-level mechanisms responsible for these
motor improvements remain to be elucidated, various studies
suggest that EES facilitates motor performance through modula-
tion of mostly afferent, dorsal pathways forwarding input to the
spinal cord (3, 15, 16). It is thought that with the engagement of
these dorsal spinal cord structures through EES in combination
with locomotor training, sensory feedback is enhanced, which
could form a new source of excitation of spinal circuits caudal to
the lesion (3, 17). This claim is further supported by evidence from
preclinical work, involving both genetic mutation models (3) and
lesion models (9). For example, elimination of sensory input
through a genetic mutation in a mouse model of SCI resulted in
impairments of locomotor recovery (3). Similarly, in a rat model of
SCI, unilateral deafferentation of the hindlimb resulted in serious
impairment of EES-induced motor recovery on the deafferented
side as compared to the nondeafferented side (9).
The dorsal root ganglion (DRG) harbors the first-order neurons
of the sensory pathway and is as such responsible for a range of
sensory processes, such as nociception (pain), mechanoreception
(pressure) as well as proprioception (body spatial position) (18).
The latter subtype of DRG neurons is associated with muscle spin-
dles through which information about muscle contraction is trans-
mitted to the central nervous system for proprioceptive
processing (3, 17). These neurons exhibit the most widespread
central projection pattern of all DRG sensory neurons and estab-
lish unique synaptic contacts with motor neurons and ventral
interneurons involved in locomotor behavior such as extensor-
flexor alternation regulation (19) and rhythm generation (3) as
studied in murine models. Specifically, muscle spindle afferents
are thought to be embedded in a so-called “selective central syn-
aptic connectivity matrix,” (3) which facilitates the transfer of mus-
cle-specific information either 1) directly to motor neurons
through functionally distinct interneurons or 2) through media-
tion of reciprocal inhibition between motor neurons (20–22),
resulting in recruitment of both monosynaptic and polysynaptic
spinal reflex pathways. It is thought that the proprioceptive sub-
type of DRG neuron is therefore in a prime position to convey
direct excitation to these spinal circuits relevant to motor behav-
ior, especially under conditions of disconnected descending input,
as is the case in SCI (3).
Although the importance of the role of afferent input for motor
recovery in SCI has been reported before, the DRG itself has not
been targeted as a source of stimulation to evoke motor
responses in patients with SCI as of yet. Apart from a preliminary
study in rats and cats (23, 24), there has been no report in the lit-
erature of the potential ability of DRG stimulation to evoke motor
responses, let alone in patients with SCI (see literature overview in
Supporting Information S1). For chronic pain, however, DRG stim-
ulation is already well known as a safe and effective treatment
(25–28), with uniquely beneficial characteristics (28), including
selectivity and subdermatomal specificity, physical lead stability,
and anatomical accessibility.
In the case of SCI, the use of DRG stimulation would target
responsible sensory neurons directly and at each spinal level indi-
vidually, presenting with potential advantages such as spatial
selectivity (28), which remains a challenging frontier for EES as
used after SCI (4, 5, 12–14). In fact, with the DRGs anatomically
separated at each level, DRG stimulation may improve spatial
selectivity as compared to EES, as the stimulation is less likely to
spread to other spinal levels, even at high stimulation amplitudes.
Moreover, given the application of DRG stimulation in chronic
pain (25–28), the necessary devices (pulse generators and leads)
are directly clinically accessible once the necessary regulatory hur-
dles are passed. Therefore, exploring the potential of DRG stimula-
tion to evoke motor responses after SCI would fill in a current
lacuna in literature and clinical practice.
The goal of the current study is to provide a first proof-of-prin-
ciple of the potential of DRG-stimulation as a new target for
neuromodulation in a case series of patients with motor complete
SCI. More specifically, the current study sets out to explore
whether DRG stimulation can lead to selective (DRG-level specific),
reproducible (over a period of days), and clinically relevant (strong
and potentially weight bearing) motor responses. We had prelimi-
nary evidence from a pilot study in chronic pain patients (see
summary in Supporting Information S2), demonstrating that
within the stimulation range of currently available clinical devices,
DRG-stimulation could facilitate strong, reproducible motor
responses in the lower extremities in these noninjured patients.
To best of our knowledge, the current study is the first to explore
the above-mentioned goals in SCI patients.
MATERIALS AND METHODS
Participants
For this study, patients with chronic motor complete SCI (ASIA
Impairment Scale [AIS] A/B) without any residual motor function
in the lower extremities were included from the investigators’
practice at Erasmus MC and the Rijndam Rehabilitation Center in
Rotterdam, the Netherlands. The level and completeness of injury
was confirmed pre-inclusion using neurological examination in
accordance to American Spinal Cord Injury Association (ASIA)
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guidelines, as performed by a specialist in rehabilitation medicine
(RO). In addition, baseline Medical Research Council (MRC) scores
of the legs were assessed by the same specialist (on a scale from
0 to 5, with 0 being “no contraction” and 5 being “normal
strength”) (29, 30). Additionally, self-reported problems with spas-
ticity were listed. Patients were included if they suffered from
motor complete SCI for >2 years and were >18 years old at the
time of inclusion. Preferably, patients with residual, bilateral upper
extremity strength were included to ensure possibility of assisted
weight-bearing testing (see “Clinical Outcome Measures”). This
was, however, not a protocolized inclusion criterion. Patients were
excluded if they were implanted with an intrathecal baclofen
pump, they suffered from anxiety or depression, had pressure
ulcers or severe contractures, were pregnant or had a life expec-
tancy less than one year.
Study Design
The current study consists of a prospective case series and
proof-of-principle study. For each individual patient, the study
period consisted of a total of five days (Fig. 1). On day 1, the
patient underwent the placement of temporary leads, external-
ized through the skin, to allow for nonsurgical removal at the end
of the study period. Subjects received DRG leads on level L4, one
on each side. This level was preferred, as the roots at this level
are known to activate the quadriceps muscles which are involved
in knee extension (31), as was confirmed in our explorative study
using DRG stimulation to evoke lower-extremity motor responses
in patients implanted with a DRG stimulator for the indication of
chronic pain (see Supporting Information Fig. S2). After successful
implantation, the patient was brought to the Department of Clini-
cal Neurophysiology for surface EMG and clinical muscle force
measurements (MRC scoring). After this first measurement ses-
sion, patients were sent home with a DRG stimulator activated at
submotor threshold level to assess potential effects of continuous
subthreshold neuromodulation. On day 5, the patients were
invited back for a second measurement session to assess the
reproducibility of motor response. The same day, the DRG leads
were removed in an outpatient setting at the Department of Pain
Medicine (as no surgery/hospital admission was necessary for
this). The study design was approved by the Erasmus Medical
Centre Medical Ethics Review Committee (METC) (MEC-2017-107,
NL60957.078.17). Prior to participation, all participants signed a
written informed consent as approved by the METC. In addition,
all patients provided consent for the publication of personal
images.
DRG-Stimulation Device Implantation
The DRG-stimulation device (Abbott, Plano, TX, USA) as used in
the current study consists of an external trial pulse generator (Pro-
claim DRG), two quadripolar percutaneous DRG-leads and a wire-
less clinician programmer device (Fig. 2). The pulse generator
allowed for a maximum range of pulse frequency (F) (4–80 Hz),
pulse amplitude (I) (0–6.000 mA), and pulse duration (D) (40–
1000 μsec) (32). The minimally invasive surgical technique has
been described earlier by members of the current research group
(26) and was performed by an experienced senior member of


























Figure 1 Overview of the experimental design as used in this study. On day
1, patients received surgical implantation of two DRG leads, which were
placed bilaterally on level L4. On days 1 and 5, EMG and clinical measure-
ments were performed. At the end of day 1, patients were sent home with
both DRG-leads activated at a submotor threshold stimulation level, and a
patient diary to fill in during the submotor threshold stimulation period at
home (marked orange). On day 5, the ability for assisted weight bearing was
also tested with both DRG leads activated according to optimal isotonic stim-
ulation parameters. At the end of day 5, leads were removed in an outpatient
clinical setting at the department of pain medicine (as no surgery/admission








Figure 2 DRG-stimulation system and intra-operative X-ray image. a. Over-
view of the Abbott DRG-stimulation kit as used in this study. 1) Temporary
quadripolar leads as placed in the study patients. Each lead holds a total of
four electrodes, which can be programmed separately. 2) The pulse generator
that was left externalized but connected to the implanted temporary leads
during the study period. 3) The clinician programmer that was used to pro-
gram the leads individually according to the stimulation protocol. The com-
plete DRG-stimulation system is currently clinically accessible for the
treatment of chronic pain. b. Overview of intra-operative X-rays as made dur-
ing the DRG-lead placement of pt #2. Vertebral segments L3, L4, and L5 are
labeled in the X-ray. As can be seen from the X-ray, the leads are placed bilat-
erally over the L4 level DRG (see white arrows), caudal to the pedicles of the
vertebral segment labeled as “L4.” [Color figure can be viewed at
wileyonlinelibrary.com]
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to minimize the lumbar lordosis. The entire procedure was per-
formed under local anesthetic (lidocaine). Sedation with propofol
and remifentanil was additionally available at the patient’s
request. Leads were placed via a percutaneous and minimally
invasive epidural approach, using a loss of resistance technique
with a Tuohy needle. Leads were inserted through a sheath and
positioned in the intervertebral foramen under the pedicle on top
of the DRG. The lead was stabilized in the epidural space with a
double loop. Correct lead position was determined by using fluo-
roscopy in AP and lateral direction and intraoperative stimulation
until motor responses (i.e., leg movement) were present upon
visual inspection.
EMG Measurements (Days 1 and 5)
The current study aimed at evoking two types of muscle
response. First, we aimed to evoke a so-called phase 1 muscle
response, a “dynamic” motor response characterized by a clear
alternation between muscle contraction and relaxation. This
response is the consequence of a lower-frequency stimulation
input, leaving time for relaxation between stimulation pulses. Sec-
ond, we aimed to evoke a phase 2 “isotonic” muscle response, a
muscle response at higher stimulation frequency and amplitude,
leading to a continuous, strong muscle contraction with a stable
tonus and no visible relaxation of the muscle.
In order to evoke both these “dynamic” muscle responses
(phase 1), as well as the “isotonic” motor responses (MRC ≥4)
(phase 2), a stimulation protocol was developed based on the pre-
viously mentioned explorative study (see Supporting Information
Fig. S2). In phase 0, we increased the pulse amplitude (I) to find
the first threshold of muscle contraction. This was done under the
minimum frequency which can be produced by the pulse genera-
tor (4 Hz). The threshold was determined by both visual clinical
feedback of the targeted muscles and the appearance of DRG-
evoked potentials on the real-time EMG traces (JD). Then, we con-
tinued to increase the amplitude in phase 1 to find the optimal
settings of I, defined as the I after which the amplitude of the
muscle response as seen in the EMG-traces did not increase any
further. In phase 2, we aimed at isotonic contractions by taking
the optimal I and increasing the pulse frequency (F) until isotonic
contractions were observed. If the maximum increase in F still did
not allow for isotonic contraction, we increased the pulse duration
(D) (also known as pulse width) to facilitate an isotonic contrac-
tion (Table 1). All stimulation protocols were performed using a
standard electrode configuration (N+ −N), assuming an ideal
placement of the DRG lead. In case of loss of muscle amplitude
during phase 2, stimulation was paused briefly (<5 min) to rest
the muscle and picked up at the last set of stimulation parame-
ters to continue above-described protocol. Only in those cases
when a full run through phase 0–2 (Table 1) (including pauses)
would not lead to isotonic contraction, we would change to new
electrode configurations and run through the protocol again. First,
a change in polarity would be attempted (N− +N), and if not suc-
cessful, more “wide-field” stimulation options (e.g., +NN−, −NN+,
etc., on a trial-and-error basis) were tried. After determination of
the optimum settings for isotonic stimulation for each leg, bilat-
eral stimulation was attempted. Based on the intrinsic settings of
the pulse generator, bilateral stimulation entailed interleaved
delivery of pulses to the bilateral DRGs (32). The personal activa-
tion thresholds and muscle force (MRC scoring) were compared
between baseline, days 1 and 5 to assess reproducibility of motor
responses.
Submotor Threshold Stimulation Protocol at Home (Days 2–4)
After the first EMG measurements, patients were sent home
with both DRG leads activated at a submotor threshold stimula-
tion level (0.10 mA [I], 4 Hz [F], and 1000 μsec [D]). This combina-
tion of stimulation parameters was predefined as a combination
of parameters expected to be far under the muscle activation
threshold, as based on the first pilot study (see Supporting Infor-
mation S2). The submotorthreshold nature of these parameters
was confirmed for each patient during the EMG measurement on
day 1.
EMG-Data Acquisition and Analysis
Responses from the rectus femoris (RF), vastus lateralis (VL),
vastus medialis (VM), biceps femoris (BF), gastrocnemius (GC),
tibialis anterior (TA), and the abductor hallucis longus (AHL) mus-
cles were recorded bilaterally with BrainRT EEG software (OSG,
Belgium) using silver-silverchloride surface electrodes at a sam-
pling frequency of 1000 Hz. In addition, paraspinal muscles (PS)
were measured to detect stimulation artifact signal and stimula-
tion onset.
The EMG data were manually annotated into 3 sec data-files in
the regions of interest before being subjected to data processing
in a custom-written data-analysis tool (Matlab R2017a). Filtering
involved detrending (fifth order Butterworth at 1 Hz), notch-filter-
ing (50 Hz), and low-pass filtering (second-order Butterworth at
100 Hz), before being subtracted by background (nonstimulated
baseline) EMG signal. For the low-pass filter, the cut-off was deter-
mined based on the maximum stimulation frequency expected to
be needed in the pilot (40 Hz based on the first pilot, see
Supporting Information S2). Apart from the detrending, no other
high-pass filter was applied to prevent the loss of signals pro-
duced by low-frequency stimulation (4 Hz). All signals and fre-
quency spectra of signals were compared prefiltering and
postfiltering to determine the presence of any filtering artifacts
and/or the loss of signal detail. To measure muscle movements,
we made use of the root mean square (RMS) of the subtracted
signal as a measure of the average power of the EMG signal (4, 5).
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Table 1 Stimulation Protocol as Used During the EMG Measurements.
Phase Amplitude (I) Frequency (F) Duration (D) Aim
Phase 0 0–6.0 mA 4 Hz 200 μsec Dynamic Contraction–Threshold I








200 μsec to 1 msec
Isotonic contraction–F/D optimization
I, pulse amplitude; F, pulse frequency; D, pulse duration.
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For visualization purposes, RMS values for each muscle (contralat-
eral and ipsilateral to stimulation) in each individual patient dur-
ing phase 1, phase 2 and bilateral stimulation were displayed
using heatmaps. Additionally, filtered 3 sec EMG traces during
phase 1, phase 2, and bilateral stimulation on days 1 and 5 were
displayed. A selection of individual traces of DRG-evoked poten-
tials was also displayed with respect to each pulse of DRG-stimu-
lation (as extracted from the artifact signal in the PS trace, see
above). All filtering and visualizations (heatmap, muscle traces)
were performed in Matlab 2017a.
Clinical Outcome Measures
A total of two clinical outcome measures were used to assess
the motor responses as evoked by DRG stimulation. Primarily,
muscle strength during phase 2 (isotonic) contractions on days 1
and 5 was measured using manual muscle testing (MMT) with the
Medical Research Council (MRC)-scoring system (on a scale from 0
to 5, with 0 being “no contraction” and 5 being “normal strength”)
(29, 30). These scores were performed during phase 2 stimulation
of one or both legs, with the subject in supine position. An MRC
score of ≥4 (with a score of “4” entailing a “movement against
gravity and resistance”) is necessary for muscle strength during
DRG stimulation to be considered feasible in a clinical setting for
SCI (e.g., to allow for assisted weight-bearing ability/standing). As
a secondary outcome measure, and mostly for demonstrative pur-
poses, the ability for the patient to come to an assisted weight-
bearing position was assessed on day 5 at the Unit of Physiother-
apy with both DRG-stimulators activated on an isotonic level. This
outcome measure was considered secondary to the MRC score, as
it was expected that a leg extension around the knee joint alone
would not be sufficient to come to independent standing (i.e., lack
of hip stability, postural control). The assisted weight bearing con-
sisted of the following components: 1) a passive patient lift sys-
tem that was slowly lowered, 2) parallel bars that could be used
for the patient to compensate using their arms as the lift was
lowered, 3) positioning of the feet by a researcher during the low-
ering to ensure proper sole-ground contact, and 4) when neces-
sary, ankle-feet orthoses on both legs to promote stability.
Patients were tested for assisted weight-bearing ability multiple
times, but never longer than five consecutive minutes of standing.
The assisted weight-bearing test was only performed when
deemed safe, that is, if a patient had sufficient remaining upper
extremity strength to compensate on the parallel bars.
Statistical Analysis
Group-level RMS values were compared between muscle pairs
(ipsilateral vs. contralateral to stimulation site) using a nonpara-
metric Wilcoxon rank sum test for independent samples, both for
data on days 1 and 5 of the study. In addition, to assess the stabil-
ity of the response, group-level RMS values were compared for
each individual muscle between day 1 and day 5 using the non-
parametric Wilcoxon signed rank test for dependent samples. Dif-
ferences were considered to be statistically significant when
p < 0.05. All statistical analyses were performed in Matlab 2017a.
Adverse Events and Side Effects
During the subthreshold stimulation period (days 2–4), all
patients were asked to keep a diary regarding: potential (changes
in) pain sensations (reported on a VAS scale), signs of autonomic
dysreflexia (e.g., elevated heart rate, headache, high blood
pressure), involuntary muscle responses or signs of other
(unwanted) side effects. During each measurement session, blood
pressure was also measured. Finally, each patient was given a
company-provided magnet (St. Jude Medical) and instructions on
how to use it to disable (and re-activate) the pulse generator in
case of signs of autonomic dysreflexia. Patients were asked to
report if, when and how long they had disabled their stimulator
during the study period.
RESULTS
Patient Baseline Characteristics
Five male patients with motor complete SCI were included
between June 2018 and December 2018 (Table 2). The mean age
was 26.6 years old (19–35 years) and the mean time since injury
was 6.6 years (4–15 years). All SCIs were a result of trauma. Levels
of SCI ranged between C4-Th5, with four patients presenting with
AIS A and one with AIS B (pt #2). Three patients (pt #1–3) had suf-
ficient core stability and muscle strength in the upper limbs for
testing of assisted weight bearing. All patients presented with an
MRC score of 0 for all lower leg muscles at baseline. All patients
presented with self-reported spasticity in the legs. None of the
patients took any anti-spasticity medication or received botulinum
toxin injections at least six months prior to inclusion of the study.
None of the patients presented with rigidity or contractures in the
lower extremities (Table 2).
Phase 1 (Dynamic) and Phase 2 (Isotonic) Muscle Response
(RMS Values)
In all patients, the stimulation protocol evoked both phase 1
(dynamic) (Fig. 3) and phase 2 (isotonic) motor response (Fig. 4),
both on day 1 and day 5 of the study (see Supporting Information
S3 Video).
For the phase 1 motor response, only the upper leg muscles
(RF, VL, VM, and BF) presented with a significant rise in RMS values
when comparing the stimulated right leg (ipsilateral) to the con-
tralateral left leg on both day 1 and day 5 of the study (p < 0.05
in all cases) (Fig. 3a,b). None of the lower leg muscles showed a
significant increase in RMS-value during stimulation. No signifi-
cant difference in RMS values for each individual muscle was
observed between measurements on day 1 vs. measurements on
day 5 (Fig. 3c), indicating a stable and reproducible response. An
overview of EMG-traces for all muscles during phase 1 stimulation
in each patient individually is depicted in the Supporting Informa-
tion Figure S4. There was no significant difference in these results
when the left leg rather than the right leg was ipsilateral to stimu-
lation (data not shown).
For the phase 2 motor response, the upper leg muscles (RF, VL,
VM, and BF) again presented with the most significant rise in RMS
value when comparing the stimulated right leg (ipsilateral) to the
contralateral left leg on both day 1 and day 5 of the study
(p < 0.01 in all cases) (Fig. 4a,b). Of the lower leg muscles, only
the TA showed a significant difference in RMS-values between the
ipsilateral vs. contralateral leg on both day 1 and 5 of the study
(Fig. 4c) (p < 0.05 and p < 0.01 for the two days, respectively), but
with lower overall RMS amplitudes as compared to the upper leg
muscles. Nevertheless, lower leg muscle involvement could be
observed under higher-amplitude stimulation, as also visible in
Supporting Information S3 Video (more on this in the Discussion).
No significant difference in RMS values for each individual muscle
was observed between measurements on day 1 vs.
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measurements on day 5 (Fig. 4c), indicating a stable and repro-
ducible response. When looking at this response in the EMG
traces of, for example, the VL, a clear acitvation can be appreci-
ated on both day 1 and day 5 (Fig. 4e,f). An overview of EMG
traces for all muscles during phase 2 stimulation in each patient
individually is depicted in the Supporting Information Figure S4.
There was no significant difference in these results when the left
leg was ipsilateral to stimulation (data not shown), or when bilat-
eral phase 2 stimulation was performed (see later on).
Bilateral Stimulation
In all patients, after isotonic stimulation parameters were deter-
mined for each leg, double lead stimulation was attempted in a
supine position (Fig. 5). This was performed to ensure the poten-
tial of evoking bilateral isotonic motor responses simultaneously,
required for weight bearing (see Supporting Information S3
Video). Double lead stimulation required an adjustment in iso-
tonic stimulation parameters in both A and/or F in a total of two
patients (pt #1 and #5) (see Fig. 6). However, there was no signifi-
cant difference in RMS values during bilateral isotonic stimulation
between the left and right leg or between day 1 and day 5 of
stimulation (Fig. 5a–c).
Muscle Force (MRC Scoring) and Weight-Bearing Ability
In all patients, isotonic stimulation presented with an extension
of the leg around the knee (see Supporting Information S3 Video).
In all patients, this was accompanied by an MRC score of ≥4 on
day 1 and day 5 (Table 3). In three of the patients (pt #1–3), bilat-
eral activation of the leads allowed for testing of assisted weight
bearing on day 5, with the help of their upper limb strength to
stabilize on the parallel bars (see Fig. 6 and Supporting Informa-
tion S3 Video). For two patients (pt #4 and #5), the lack of arm
strength and core stability did not allow for safe testing of
assisted weight bearing on day 5.
Activation Thresholds Day 1 vs. Day 5
Great heterogeneity in activation thresholds of phase 1 (0.5–
2.5 mA) as well phase 2 (2.3–6.0 mA) motor responses could be
observed across, as well as within patients when comparing day 1
vs. day 5 parameters (see Supporting Information Fig. S4). An
overview of the activation thresholds for all the measured mus-
cles can be found in Table 4.
Amplitude Response Curves
Amplitude response curves could be made for all patients on
both day 1 and day 5 during phase 2 of stimulation, depending
on the range of parameters as used for stimulation for each indi-
vidual patient (due to heterogeneity in activation thresholds
across patients, different ranges of parameters could be covered
per patient, see Supporting Information S4). Noticeably, muscle
recruitment patterns across different amplitudes resulted in het-
erogeneous curves across and within patients between day 1 vs.
day 5. However, in all patients, the upper leg muscles consisting
of VL, VM, RF (of the m. quadriceps femoris) and BF were recruited
most, followed by the TA (activated mostly in pt #3 and pt #4)
and the AH (activated mostly in pt #1, #3, and pt#4). In addition,
in patient 3 (TA) and patient 4 and 5 (AH), contralateral muscles
were at times recruited during increase of amplitude (see
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Figure 3 Overview of patient- and group-level analysis of muscle response during phase 1 of our stimulation protocol (increase in amplitude during stimulation
aimed at dynamic muscle response). a,b. Heat plots representing the muscle response of ipsilateral vs. contralateral muscles per individual patient during phase 1
of stimulation on day 1 vs. day 5 of the study. At first glance, the highest RMS values were achieved in the upper leg muscles in patients 1, 2, and 5. c. 1) Boxplots
depicting the group-level RMS values of ipsilateral (filled blue boxes) and contralateral (blue contoured boxes) muscles responses on day 1 and day 5 of stimulation.
At a group level, the right upper legs muscles (RF, VL, VM, and BF) ipsilateral to stimulation present with significantly higher RMS values as compared to their contra-
lateral counterparts in the left leg on both days 1 and 5 (p < 0.05 in all cases using a Wilcoxon rank sum test, see vertical lines). For the lower leg muscles, differences
in RMS values were nonsignificant on both days 1 and 5. None of the muscles, either ipsi- or contralateral, showed a significant difference in RMS value between day
1 and day 5 of stimulation (p > 0.05 in all cases using a Wilcoxon signed rank test, see horizontal lines). c. 2) Zoom-in on a section of the boxplots in C.1 (see green
range on the y-axis), depicting more clearly the contralateral muscle responses on day 1 and day 5 of stimulation (blue contoured boxes). All contralateral responses
were < 50 μV in amplitude. d. Zoom-in on 500 msec of the data selected from a ROI depicted by the red box in panel e. Individual traces of DRG-evoked potentials
are now visible with respect to the DRG-pulse pattern. A total of two pulses is visible in this time window, matching with the 4 Hz pulse frequency delivered by the
stimulator. e,f. Example EMG-traces of the ipsi- and contralateralVL muscle during phase 1 stimulation on days 1 and 5 of the study. Differences between stimulated
vs. nonstimulated side are clearly visible, with the frequency used during phase 1 stimulation reflecting in the frequency of the muscle contractions. Corresponding
stimulation parameters and electrode configuration are depicted in the right columns. See supplement 4 for patient-specific details. I, pulse amplitude; F, pulse fre-
quency; D, pulse duration, BF, biceps femoris; PS, paraspinal; RF, rectus femoris; VL, vastus lateralis; VM, vastus medialis; GC, gastrocnemius, TA, tibialis anterior,
AH, abductor hallucis; RMS, root mean square; R, right; L, left. *p < 0.05, ns = not significant. [Color figure can be viewed at wileyonlinelibrary.com]
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Figure 4 Overview of patient- and group-level analysis of muscle response during the end of phase 2 of our stimulation protocol (isotonic muscle response). a,b. Heat plots
representing the muscle response of ipsilateral vs. contralateral muscles per individual patient during isotonic motor response (the end of phase 2 of stimulation) on day 1 vs.
day 5 of the study. Again, the highest RMS values were achieved in the upper leg muscles for all patients, although the lower leg muscles display higher amplitudes as well
when comparing to phase 1 stimulation (Fig. 3). c. Boxplots depicting the group-level RMS values of ipsilateral (filled blue boxes) and contralateral (blue contoured boxes) mus-
cle responses on day 1 and day 5 of stimulation. At a group level, the right upper legs muscles (RF, VL, VM, and BF) ipsilateral to stimulation present with significantly higher
RMS values as compared to their contralateral counterparts in the left leg on both day 1 and 5 (p < 0.01 in all cases using a Wilcoxon rank sum test, see vertical lines). The lower
leg muscles present with less clear activation patterns, with on day 1 a significant rise in RMS values for the ipsilateral TA and AH (p < 0.05 and p < 0.01, respectively), while on
day 5, this was the case for the ipsilateral GC and TA (p < 0.05 and p < 0.01, respectively). However, overall RMS-values for lower leg muscles were lower in amplitude as com-
pared to the upper leg muscles as also seen in panels a and b. None of the muscles, either ipsi- or contralateral, showed a significant difference in RMS-value between day 1
and day 5 of stimulation n (p > 0.05 in all cases using a Wilcoxon signed rank test, see horizontal lines). d. Zoom-in on 500 msec of the data selected from a ROI depicted by the
red box in panel e. Individual traces of DRG-evoked potentials are now visible with respect to the DRG-pulse pattern. A total of ten pulses is visible in this time window,
matching with the 20 Hz pulse frequency delivered by the stimulator. e,f. Example EMG-traces of the ipsi- and contralateral VL muscle during isotonic stimulation on day 1 and
day 5 of the study. Differences between stimulated vs. nonstimulated side are clearly visible, with continuous activation of the muscle depicted on the side ipsilateral to stimula-
tion. Corresponding stimulation parameters and electrode configuration are depicted in the right columns. See supplement 4 for patient-specific details. I, pulse amplitude; F, pulse
frequency; D, pulse duration, BF, biceps femoris; PS, paraspinal; RF, rectus femoris; VL, vastus lateralis; VM, vastus medialis; GC, gastrocnemius, TA, tibialis anterior, AH, abductor hal-
lucis; RMS, root mean square; R, right; L, left. *p < 0.05, **p < 0.01, ns = not significant. [Color figure can be viewed at wileyonlinelibrary.com]
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Figure 5 Overview of patient- and group-level analysis of muscle response during bilateral isotonic stimulation. a,b. Heat plots representing the muscle response per
individual patient during bilateral isotonic stimulation on day 1 vs. day 5 of the study. As can be seen clearly from the heatplots, especially upper leg muscles, now in
both the right and left leg, seem to be involved. c. Boxplots depicting the group-level RMS values of ipsilateral (filled blue boxes) and contralateral (blue contoured
boxes) muscles responses on day 1 and day 5 of stimulation. None of the muscles in the right leg presented with significantly higher RMS-values as compared to their
contralateral counterparts in the left leg on both day 1 and 5 (p > 0.05 in all cases using a Wilcoxon rank sum test, see vertical lines). Overall RMS values for lower leg mus-
cles were lower in amplitude as compared to the upper leg muscles. None of the muscles, either in the left or right leg, showed a significant difference in RMS-value
between day 1 and day 5 of stimulation (p > 0.05 in all cases using a Wilcoxon signed rank test, see horizontal lines). d. Zoom-in on 500 msec of the data selected from
a ROI depicted by the red box in panel e. Individual traces of DRG-evoked potentials are now visible with respect to the DRG-pulse pattern. A total of eight pulses is visi-
ble in this time window, matching with the 16 Hz pulse frequency delivered by the stimulator. e,f. Example EMG traces of the VL muscle during bilateral isotonic stimula-
tion on day 1 and day 5 of the study. Corresponding stimulation parameters and electrode configuration are depicted in the right columns. For all patients, bilateral
isotonic stimulation lead to a muscle response with an MRC score of 4 and higher. See supplement 4 for patient-specific details. I, pulse amplitude; F, pulse frequency;
D, pulse duration, BF, biceps femoris; PS, paraspinal; RF, rectus femoris; VL, vastus lateralis; VM, vastus medialis; GC, gastrocnemius, TA, tibialis anterior, AH, abductor hallucis;
RMS, root mean square; R, right; L, left. *p < 0.05, **p < 0.01, ns, not significant. [Color figure can be viewed at wileyonlinelibrary.com]
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DRG-STIMULATION IN MOTOR COMPLETE SCI
Frequency Response Curves
Frequency response curves could be made for all patients on
both day 1 and day 5 within the range of 4–24 Hz, depending on
the parameters as used for stimulation for each individual patient
(due to heterogeneity in activation thresholds across patients, dif-
ferent ranges of parameters could be covered per patient, see
Supporting Information S4). Noticeably, rise in frequency was
accompanied by less clear rises in RMS values, in line with results
of our first explorative study in chronic pain patients (see
Supporting Information S2). What is more, a rise in frequency at
times was accompanied by a drop in EMG-amplitude, different
per patient (see Supporting Information S4), potentially explained
by muscle fatigue (more on this in the discussion). Increase in
frequency at times resulted in recruitment of contralateral mus-
cles such as in patient 1 (AH) and patient 2 (TA).
Adverse Events and Side Effects
None of the patients reported any (serious) adverse events dur-
ing the study period (including signs of autonomic dysreflexia),
nor were any (serious) adverse events observed by the research
team. No abnormal changes in blood pressure were measured
during stimulation. None of the patients presented with lead/
wound infection during/after the study. None of the patients
(including pt #2 with AIS B) reported any painful sensory percep-
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Figure 6 Overview of assisted weight-bearing results in the n = 5 patients included in this case series. Weight-bearing assistance consisted of 1) a passive patient
lift, 2) parallel bars for upper extremity compensation, 3) positioning of the feet by a researcher and when necessary 4) bilateral ankle-feet orthoses. a. Results for
patient #1, who was able to achieve assisted weight bearing. In supine position, the MRC-scores for the right (5) and left (5) leg respectively, also predicted a
strong isotonic contraction with potential for weight bearing. b. Results for patient #2, who was able to achieve assisted weight bearing. In supine position, the
MRC-scores for the right (5-) and left (5-) leg, respectively, also predicted a strong isotonic contraction with potential for weight-bearing. c. Results for patient #3,
who was able to achieve assisted weight bearing. In supine position, the MRC-scores for the right (5) and left (5) leg, respectively, predicted a strong isotonic con-
traction with potential for weight bearing. In upright position, the patient’s posture did not seem as stable as pt. 1 and pt. 2. d. Results of patient #4, who was not
able to participate in the assisted weight-bearing test due to lack of upper extremity strength. The image depicts bilateral isotonic response in supine position on
day 5. The MRC-scores for the right (4) and left (4) leg did, however, predict potential weight bearing, although the scores were slightly lower as compared to the
other patients. e. Results of patient #5, who was not able to participate in the assisted weight-bearing test due to lack of upper extremity strength. The image
depicts bilateral isotonic response in supine position on day 5. The MRC scores for the right (5) and left (4) leg did, however, predict potential weight bearing. *All
EMG recordings and MRC-scorings were performed in supine position on day 5, prior to testing of assisted weight bearing. MRC, Medical Research Council; I, pulse
amplitude; F, pulse frequency; D, pulse duration; mV, millivolt; RF, rectus femoris; VL, vastus lateralis; VM, vastus medialis; BF, biceps femoris; R, right; L, left. [Color
figure can be viewed at wileyonlinelibrary.com]
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magnet to disable the pulse generator during the subthreshold
stimulation period.
DISCUSSION
This study is the first of its kind to demonstrate the potential of
the DRG as a new target for reproducible and potentially weight-
bearing muscle recruitment in patients with motor complete SCI.
In all patients, bilateral DRG-stimulation on the L4 level was able
to evoke bilateral isotonic motor responses recruiting predomi-
nantly upper leg muscles (Fig. 4), leading to knee extension. In
three of our patients with sufficient core-stability and arm
strength, these motor responses were strong enough to reach
assisted weight bearing (Fig. 6 and Table 3). All muscle responses
were reproducible over a five-day period (Figs. 3–5).
11
Table 3 Overview of the MRC Scores During Phase 2 (isotonic) Contractions of Five Patients on Days 1 and 5 of the Current Study.
Patient MRC* score baseline MRC* score day 1 MRC* score day 5
1-Right 0 5 5
1-Left 0 4 5
2-Right 0 5- 5-
2-Left 0 4 5-
3-Right 0 5 5
3-Left 0 5 5
4-Right 0 4 4
4-Left 0 4 4
5-Right 0 5 5
5-Left 0 4 4
*MRC, Medical Research Council.
Table 4 - Overview of the Activation Thresholds of All Patients (n = 5) on Days 1 and 5.
Patient and side of stimulation Parameter Phase 1 (dynamic) Phase 2 (isotonic)
Day 1 Day 5 Day 1 Day 5
1-Right I (mA) 0.9 0.5 3.6 3.6
F (Hz) 4 4 20 14
D (μsec) 200 200 200 200
1-Left I 1.0 1.2 2.5 4.4
F 4 4 20 16
D 200 200 200 200
2-Right I 1.2 1.2 5.2 6.0
F 4 4 22 20
D 200 200 200 200
2-Left I 0.8 2.0 4.5 6.0
F 4 4 20 20
D 200 200 200 200
3-Right I 1.2 0.95 5.2 5.6
F 4 4 20 20
D 200 200 200 200
3-Left I 1.5 1.5 4.8 6.0
F 4 4 20 20
D 200 200 500 500
4-Right I 0.8 0.6 6.0 6.0
F 4 4 16 16
D 200 200 400 500
4-Left I 2.5 2.3 5.0 4.0
F 4 4 10 20
D 200 200 350 600
5-Right I 0.8 1.2 2.3 3.3
F 4 4 14 22
D 200 200 500 200
5-Left I 1.2 1.1 2.5 3.4
F 4 4 20 20
D 200 200 200 200
I, pulse amplitude (mA); F, pulse frequency (Hz); D, pulse duration (μsec).
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DRG-STIMULATION IN MOTOR COMPLETE SCI
In its currently studied form, isotonic DRG stimulation could be
potentially beneficial for independent transfers requiring weight-
bearing ability. The dynamic muscle responses as studied in the
context of this manuscript could be a potentially interesting, inter-
nalized alternative to functional electrical stimulation (FES) of mus-
cles used to combat muscle atrophy and bone density loss (33, 34).
Noticeable, however, was the significant intersubject variability
in threshold values for activation of phase 1 and phase 2 move-
ments, pointing out the need for personalized stimulation param-
eters, as is also common in EES (7). What is more, a rise in
frequency at times was accompanied by a drop in EMG-ampli-
tude, as especially visible in our frequency response curves (see
Supporting Information S4). This seemed only to occur in those
occasions when at high amplitude (end of phase 1) a step-wise
increase in frequency was performed with longer pauses between
each step. This might indicate the presence of muscle fatigue,
which could pose a challenge for future endeavors aiming at
long-lasting weight bearing for safe and independent transfers.
However, as the drop in amplitude seemed to occur at particular
frequencies, different per patient (see Supporting Information S4),
this phenomenon might also be explained by a more frequency-
specific drop in muscle amplitude. Future studies aiming for mul-
tilead stimulation and more long-lasting, nonassisted weight-bear-
ing, should focus on overcoming potential muscle fatigue
problems, for example, by combining stimulation with (muscle)
training, as is already common in EES (35–37).
Stimulation, Training, and Assisted Weight Bearing
In contrast to most EES studies so far (4, 5, 8, 12–14), our short-
term DRG-stimulation was not aimed at subject-driven volitional
movement, but rather stimulation-driven motor responses, recruiting
the synaptic reflexes directly. We sent our patients home with the
DRG-stimulator still activated at submotor threshold level to assess a
potential change in stimulation parameters needed for muscle
recruitment and/or changes in evoked muscle force (Fig. 1). The sub-
threshold stimulation did not lead to any significant changes in
RMS-values of any of the motor responses on day 5 as compared to
day 1 (Figs. 3–5) as measured in the EMG in supine position.
This is not surprising as the potential neuromodulation induced
plasticity or changes in muscle recruitment require longer periods
of time and rehabilitation, as known from EES literature (4, 5, 8, 12–
14). However, a recent study reported immediate effects of EES on
restoration of volitional motor control in patients with chronic
motor complete SCI (7) without any prior rehabilitation, suggesting
a second plasticity-independent mechanism. The potential of DRG
stimulation to achieve this immediate regain of volitional control
has not been addressed in our study and remains to be elucidated.
Similarly, our assisted weight-bearing test was performed with-
out any prior (activity based) training and under immediate DRG-
stimulation only. The assisted weight-bearing test in our study was
considered secondary to the MRC score as an outcome measure, as
it was expected that a leg extension around the knee joint alone
would not be sufficient to come to independent standing (i.e. due
to lack of hip stability, postural control). We have indeed seen that
in those patients lacking complete bilateral arm function (pt. #4
and #5), we were not able to successfully perform the assisted
weight-bearing measurements (see Fig. 6). Previous work using EES
over the lumbosacral spinal cord in combination with stand train-
ing for a period of months in four clinically motor complete
patients with SCI, demonstrated regain of the patients’ ability for
full weight-bearing standing with minimal need for self-balance
and external knee or hip extension assistance when the epidural
stimulation was on (35). In a follow-up paper studying one of these
patients throughout more than three years of activity-based train-
ing with EES, the authors report the patient’s ability to stand with
the stimulator turned off, indicating involvement of neuronal plas-
ticity (36). Similarly, an individual case of motor complete SCI
implanted with a lumbosacral epidural stimulator was reported to
present with an independent standing ability within two weeks of
EES motor training (37). Additionally, combined training and non-
invasive transcutaneous spinal cord stimulation (tSCS) between ver-
tebral levels T11-T12 or L1-L2 in a range of patients with different
levels of SCI (AIS A-C) demonstrated a regain of self-assisted stand-
ing with minimal assistance provided to the knees or hips (38). In
our case, no training component was involved in the study proce-
dure, and the assisted weight-bearing test was performed on day 5
only. Nevertheless, the targeted L4-level related knee extension in
supine position, was also present in a standing position for pt. #1–
3. Where the above-mentioned techniques of EES and tSCS also
reported additional nonassisted hip extension, we observed the
absence of hip stability in our patients, although not quantified.
This could be explained by the fact that we aimed to target L4 spe-
cifically, while the previously mentioned experiments had access to
the full lumbosacral spinal cord. Future experiments using multi-
lead DRG-stimulation, combined with the previously mentioned
training, could allow for better comparisons. As we will discuss later
on in the limitations section of this discussion, these future studies
will have to include a wider range of quantifiable measures and
assistance methods to assess weight-bearing standing ability using
DRG stimulation more objectively.
Heterogeneity, Selectivity, and Current Spread
In this context, it is also interesting to note the heterogeneity
in muscle recruitment across patients, as well as the recruitment
of non-L4 specific distal muscles (e.g., the AHL) (Fig. 4) and contra-
lateral muscles, although the latter nonsignificant using group-
level statistics (Figs. 3–5). This cross talk is known in literature on
DRG-stimulation for the treatment of chronic neuropathic pain
and is thought to occur as electrical current spreads through the
Lissauer tract. As such, in chronic pain treatment, it is not unusual
to target specific dermatomes related to the perceived pain by
stimulating spinal levels usually not ascribed to these derma-
tomes (39). The involvement of these distal muscles, however,
coincided with relatively small amplitudes in the EMG. Neverthe-
less, distal muscle involvement was visible (e.g., plantar flexion as
seen in Supporting Information S3 Video ) as discussed in the
Results section. This discrepancy most likely involves EMG scaling
of large, proximal muscles of the lower limb compared to smaller,
distal muscles. Although first reaction to the above-described
potential current spread would be to counter-act such cross talk
to enhance spatial selectivity necessary for the temporal dynamics
underlying locomotion, it could also be valuable to harness such
cross talk to elicit multijoint movements, such as a combination
of knee extension and plantar flexion described above.
Another possible scenario to consider within the realm of current
spread, is direct ventral root (VR) activation, which would cancel out
the potential benefits of dorsal recruitment as mentioned in the
introduction. Rather than having artificial afferent input enter the spi-
nal cord dorsally and drive motor response through mono- and poly-
synaptic spinal circuitry, the VR-activation scenario would entail a
direct activation of muscles, without spinal modulatory involvement
(20–22). However, it is important to note that direct VR stimulation
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would be a less likely scenario to favor. First of all, given the dorsal
placement of the lead per conventional guidelines in pain treatment,
the DRG should be the primary target (see also Fig. 2b). In fact, com-
putational literature modeling the effects of DRG-stimulation tells us
that it is highly likely that even the most ideal dorsal placement of
the lead, results in an electrical field impacting only a portion of the
DRG’s fibers (24) and neuronal population (40). Our data show that
we were able to evoke motor responses using amplitudes as low as
500 μA (Table 4), which would make a direct VR activation unlikely
given the anatomical distance >5 mm between the dorsal aspect of
the L4 DRG and the VR in the average human (41, 42). Finally, the
observed contralateral recruitment of muscles, although sparse, is an
argument in favor of recruitment of muscles through spinal reflexes,
rather than through direct VR stimulation. At higher stimulation
amplitudes, however, the possibility of VR recruitment becomes
more likely and should therefore be considered in future experimen-
tal and especially computational studies.
Lastly, it is interesting to note that all patients presented with self-
reported transfer-evoked spasticity at time of inclusion, without any
rigidity or contractures in the muscles and joints. Although an enig-
matic mechanism in itself, spasticity is thought to be the result of a
combination hyperexcitability of interneurons in the spinal cord and
decrease of postsynaptic inhibition (43, 44). Part of our future efforts
will focus on determining to what extent the presence of spasticity,
as well as other ways to interrogate the sensory system (e.g., motor
reflexes), would be important for presurgical screening and predic-
tion of DRG-stimulation treatment success.
The Potential Advantage of DRG Stimulation
Looking for new targets such as the DRG for neuromodulation
in a SCI setting can be advantageous for several reasons. First of
all, the percutaneous technique of the surgical placement of the
DRG leads is considered less invasive than the laminectomy nec-
essary for EES when using paddle electrodes. The lead-placement
over the DRG in the neuroforamen, enhances the physical stabil-
ity, decreasing the risk of lead migration due to postural changes
as seen in EES (28), while remaining equally as safe as EES (45).
Furthermore, the opportunity to place the lead over the DRG may
also promote further spatial selectivity, as it would facilitate stimu-
lation to each spinal level separately (28), which remains a chal-
lenging but essential frontier in EES (46). What is more, the
somatotopic make-up of the DRG (28, 47) shows further potential
for intra-DRG selectivity, and as such, for selectivity of muscle
groups relevant for different stages of human locomotion. In the
context of chronic pain, these selectivity advantages of DRG stim-
ulation have led to superiority of the DRG in terms of clinical out-
come as compared to EES (28). In other experimental animals
reports targeting the DRG for sensory feedback, so-called
“microstimulation” of the DRG confirms the level of selective
recruitment which can be achieved (48).
In the current study, we demonstrate significant changes in RMS
values of predominantly upper leg muscles involved in knee exten-
sion, indicating a reasonable level of spatial selectivity. In addition,
this selectivity remained stable over a period of five days. However,
we believe that the potential spatial selectivity could not be
harnessed completely, with at times lower leg muscles or contralat-
eral muscles being recruited (although predominantly nonsignifi-
cant and lower in their RMS values). The most likely room for
further improvement of selectivity lies is in increasing the limited
spatial selectivity inherent to the quadripolar DRG leads. Intra-oper-
ative electrophysiology during placement of next-generation,
spatially selective leads, could further facilitate harnessing of DRG-
somatotopy using microstimulation techniques.
With the potential advantageous aspects to DRG-stimulation in
mind, it is warranted to consider future research looking into DRG
stimulation as a means for regaining of standing and/or walking. The
obvious trade-off of EES as compared to DRG-stimulation in this
effort is the fact that multilevel DRG stimulation with spatially selec-
tive leads will have to be enabled in order to recruit all relevant mus-
cles involved in locomotion. First of all, multiple leads will have to be
implanted bilaterally which might cancel out the previously men-
tioned minimally invasive nature of lead placement. Additionally,
pulse generators currently available on the market will need to be
adjusted to facilitate the multilead stimulation. Combination place-
ments of both SCS and DRG-leads to increase recruitment selectivity
in clinically relevant levels (e.g., for postural stability or bladder con-
trol), would be an additional interesting possibility to investigate.
Study Limitations
The current study is prone to several limitations. First, only
male, relatively young patients were included. It is important to
further investigate the observed responses against the backdrop
of patient heterogeneity within SCI (7). Second, our experimental
design required a measurement session on the same day as lead
implantation. As such, electrical stimulation settings might have
been influenced by tissue reaction after placement, including
edema, as is also the case in lead placement for chronic pain (27).
Last, the clinical measurements of muscle force using the MRC-score
were accompanied by an assisted weight-bearing ability test with
the help of parallel bars and a patient lift system (our secondary out-
come). This test was limited in its conclusions, especially given the
lack of activation of other essential muscles necessary for stability
and standing, as well as the compensatory use of arm muscle
strength during standing. Additionally, the component of assistance
could not be quantified due to the fact that only a passive patient lift
was available, and no force sensors were used to measure force in
the upper extremities during parallel bar compensation. Additional
muscle force measurements, such as by using dynamometers, will
aid in objectifying the actual muscle strength in future studies.
Conclusion
DRG-stimulation using the stimulators and leads available on the
market for chronic pain, allowed for strong and reproducible iso-
tonic motor responses in the upper leg muscles of patients with
chronic motor complete SCI, enough to potentially enable weight
bearing. With the minimally invasive surgical placement of the lead
in mind, as well as the potential clinical benefits of spatial selectivity,
future research on DRG-stimulation in a SCI setting is warranted.
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SUPPORTING INFORMATION
Additional supporting information may be found online in the
supporting information tab for this article.
COMMENT
This is a very interesting and important study as it is the first to
test the effects of dorsal root ganglion (DRG) stimulation on the
recovery of motor function after spinal cord injury (SCI). These results
are very timely as a growing number of groups are using epidural
spinal cord stimulation (eSCS) to boost motor function after spinal
cord injury. Although the mechanism of action remains unclear, the
commonly held view is that eSCS activates large diameter primary
afferent neurons, activating motor neurons trans-synaptically. This
paper demonstrates a different approach for stimulating primary
afferent neurons by placing electrodes on the DRG. This study tested
this approach in 5 subjects with severe spinal cord injury and the
results demonstrate clear and significant effects on muscle activation,
providing early evidence supporting the potential benefits of this
method. This work offers an innovative approach for recovering
motor function after SCI, which is currently untreatable and results in
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